News: Pharma
Home News: Pharma
Pharmaceutical Industry News, Drugs, Nutraceuticals, Vitamins, and Related
Eularis Releases First-Ever Pharma Study: ROI of Pre-Launch Named Patient Programs
NEW YORK, N.Y. and LONDON, U.K. -- Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP),...
Epeius Biotechnologies Rexin-G® for Metastatic Cancer Highlighted by National Cancer Institute Journal
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a...
Eularis Analyzes Most Effective Generics Defense Strategies with New Pharma Industry Report
NEW YORK, N.Y. and TOKYO, JAPAN -- Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of...
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
Eularis Challenges Pharma Industry in 2008: Are You Measuring the Wrong Things
LONDON UK, and TOKYO Japan -- With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority...
Intravenous Infusions of Epeius Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue...
OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies
RICHMOND, Texas -- CYNACON / OCuSOFT (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to...
Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes
SAN MARINO, Calif. -- ASCO 2008 -- Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene...
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et...
